New perspectives on over active bladder: Quality of life impact, medication persistency, and treatment costs

American Journal of Managed Care

Volumn 11, Issue SUPPL. 4, 2005, Pages

  Mullins, C Daniel ^a   Subak, Leslee L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

OXYBUTYNIN; TOLTERODINE;

COST CONTROL; DRUG COST; ECONOMIC ASPECT; EDITORIAL; HUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; WELLBEING; XEROSTOMIA; ARTICLE; HEALTH CARE COST; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; UNITED STATES; URINE INCONTINENCE;

HEALTH CARE COSTS; HUMANS; PATIENT COMPLIANCE; QUALITY OF LIFE; UNITED STATES; URINARY INCONTINENCE;

EID: 22544456879     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (23)

1. Stewart WF, Van Rooyen JB, Cundiff CW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327-336.
2. Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of difference in definition, population characteristics, and study type. J Am Geriatr Soc. 1998;46:473-480.
3. Wilson L, Brown JS, Shin GP, Luc KO, Subak LL. Annual direct cost of urinary incontinence. Obstet Gynecol. 2001;98:398-406.
4. Tannenbaum C, DuBeau CE. Urinary incontinence in the nursing home: practical approach to evaluation and management. Clin Geriatr Med. 2004;20:437-452, vi.
5. Prochoda KP. Medical director's review of urinary incontinence in long-term care. J Am Med Dir Assoc. 2002;3(1 suppl):S11-S15.
6. Brown JS, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc. 2000;48:721-725.
7. Wagner TH, Hu TW, Bentkover J, et al. Health-related consequences of overactive bladder. Am J Manag Care. 2002;8(19 suppl):S598-S607.
8. Shih YC, Hartzema AG, Tolleson-Rinehart S. Labor costs associated with incontinence in long-term care facilities. Urology. 2003;62:442-446.
9. Ko Y, Lin SJ, Salmon JW, Bron M. The impact of urinary Incontinence on quality of life of the elderly. Am J Manag Care. 2005;11:S103-S111.
10. Shaw C. A review of the psychosocial predictors of help-seeking behaviour and impact on quality of life in people with urinary incontinence. J Clin Nurs. 2001; 10:15-24.
11. Hunskaar S, Sandvik H. One hundred and fifty men with urinary incontinence. III. Psychosocial consequences. Scand J Prim Health Care. 1993;11:193-196.
12. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004;63:461-465.
13. Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology. 1998;51:355-361.
14. Zhou SZ, Jensen G. Insurance claims costs for overactive bladder disorder. Drug Benefit Trends. 2001;13: 45-58.
15. Lemack GE. Overactive bladder: optimizing quality of care. Am J Manag Care. 2001;7(2 suppl):S46-S61.
16. Jumadilova Z, Zyczynski T, Paul B, Narayanan S. Urinary incontinence in nursery home: resident characteristics and prevalence of drug treatment. Am J Manag Care. 2005;11:S112-S120.
17. Mitteness LS, Barker JC. Stigmatizing a "normal" condition: urinary incontinerce in late life. Med Anthropol Q. 1995;9:188-210.
18. Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with overactive bladder pharmacotherapy in a medicaid population. Am J Manag Care. 2005;11:S121-S129.
19. O'Conor RM, Johannesson M, Hass SL, Kobelt-Nguyen G. Urge incontinence. Quality of life and patients' valuation of sympton reduction. Pharmacoeconomics. 1998;14:531-539.
20. Fantl J, Newman D, Colling J. Clinical Practice Guideline Number 2: Urinary Incontinence in Adults: Acute and Chronic Management. Rockville, Md: Agency for Health Care Policy and Research; 1996.
21. Roberts R, Garely A, Bavendam T. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults. Am J Manag Circ. 2005;11:S158-S162.
22. Perfetto EM, Subedi P, Jumadilova Z. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin. Am J Manag Care. 2005;11:S150-S157.
23. Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA. Economic impact of extended-release tolterodine versus extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care. 2005;11:5140-5149.